Core Insights - Bionano Genomics showcased the advancements of Optical Genome Mapping (OGM) in addressing constitutional genetic disorders at the Bionano Symposium 2026, emphasizing its unique capabilities in detecting structural variants that traditional methods often miss [1][11] Group 1: OGM Applications and Impact - OGM provides unbiased, comprehensive genome-wide structural variant detection, enhancing the interpretation of complex rearrangements in genetic disorders [2] - The technology is transforming research in rare and unresolved disorders by bridging gaps between cytogenetics and molecular genomics, revealing variants overlooked by conventional methods [3] - In a study on autism spectrum disorder (ASD), OGM identified relevant variants in 24% of cases, demonstrating its effectiveness in detecting complex genetic alterations [4] Group 2: Research Findings and Case Studies - OGM has shown utility in reproductive genetics, uncovering cryptic translocations in recurrent pregnancy loss that traditional karyotyping often misses, thus aiding genetic counseling [5] - Studies highlighted OGM's ability to resolve rare constitutional rearrangements and complex copy number variations, improving understanding in unresolved cases across diverse populations [6] - Research demonstrated OGM's capability to detect structural variants associated with conditions like fascioscapulohumeral muscular dystrophy and infertility, emphasizing the need for population-specific OGM databases [7] Group 3: Statistical Insights - In a cohort of 133 subjects with rare diseases, OGM identified pathogenic or likely pathogenic variants in 20% of subjects, with a notable 12% success rate in subjects previously testing negative by chromosomal microarray analysis and whole exome sequencing [9] Group 4: Symposium Highlights and Future Directions - The symposium featured over 1,200 participants from 73 countries, showcasing the global interest in OGM and its applications in genetic research [1] - Panel discussions focused on best practices for OGM implementation and strategies for resolving complex constitutional disorders, indicating a collaborative approach to advancing genetic research [10] - The ongoing symposium will continue to explore genome landscape analysis and feature a scientific poster competition, highlighting the commitment to innovation in genomic research [12]

VERO BEACH, Fla., Feb. 26, 2026 (GLOBE NEWSWIRE) -- BevPoint Capital LP (“BevPoint”), in connection with its proposed transaction with Okmin Resources, Inc. (OTCQB: OKMN) as previously disclosed in filings with the Securities and Exchange Commission (the “SEC”), today announced an ambitious strategic initiative aimed at creating immersive, heritage-based hospitality destinations in multiple markets throughout the US, that celebrate the unique character, culture, and craftsmanship of local communities. BevPo ...

– Training will consist of an interactive clinical education program highlighting real world application of the SynCardia Total Artificial Heart in advanced heart failure patients –TUCSON, Ariz., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), parent company of SynCardia Systems LLC, maker of the world’s first total artificial heart approved by both the U.S. FDA and Health Canada, today announced it will participate in the inaugural “Hands-On Training ...

Core Insights - StoneX Group Inc. has launched a digital asset lending capability through its division, StoneX Digital, enhancing its brokerage and financing services for institutional clients [1][2]. Group 1: Digital Asset Lending Capability - The new lending capability connects institutional clients to digital asset markets, providing spot execution, listed products, and financing solutions within a single framework [2][3]. - This initiative aims to support clients in accessing additional liquidity and capital efficiency while maintaining exposure to digital assets [2][4]. - The initial collateral for the lending program will be Bitcoin, with plans to include additional large-cap digital assets as client demand grows [4]. Group 2: Market Demand and Infrastructure - Institutional market participants are increasingly seeking financing tools that integrate both digital and traditional asset workflows [3]. - StoneX developed this capability to meet the growing demand for integrated digital asset services aligned with established financial market standards [5]. - The lending capability builds on StoneX's existing brokerage and risk management infrastructure, facilitating the integration of digital asset financing into broader portfolio strategies [4]. Group 3: Company Overview - StoneX Digital was launched in June 2022 to provide institutional clients with digital asset trading tools and market access within a regulated framework [5]. - StoneX Group Inc. is a Fortune 50 company headquartered in New York City, serving over 80,000 commercial and institutional clients across more than 80 offices globally [6].

Core Insights - Heron Therapeutics reported a 65% year-over-year net revenue growth in its Acute Care franchise, achieving $154.9 million in net revenue for 2025 and providing guidance for 2026 net revenue between $173 million and $183 million, with adjusted EBITDA expected to be between $10 million and $20 million [1][3]. Financial Performance - The Acute Care franchise experienced a revenue growth of 57.3% year-over-year in Q4 2025 and 65.1% for the full year 2025 compared to 2024, indicating strong commercial acceleration [4]. - Total net revenue for 2025 was $154.9 million, up from $144.3 million in 2024, reflecting a 7.4% increase [9]. - For Q4 2025, total net revenue was $40.6 million, slightly down from $40.8 million in Q4 2024, marking a 0.5% decrease [10]. Product Updates - ZYNRELEF, a key product, received a permanent product-specific J-Code (J0668) from CMS, effective October 1, 2025, which streamlines reimbursement processes [7]. - The transition to the Vial Access Needle for ZYNRELEF has been completed, enhancing product handling and sterility in hospitals and surgical centers [7]. - APONVIE, another significant product, was included in the Fifth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting, highlighting its clinical importance [7]. Market Position and Strategy - The CEO emphasized that the company is entering 2026 with strong momentum, driven by strategic decisions that have unlocked the potential of its assets, particularly ZYNRELEF [2]. - The company is focused on expanding demand signals and improving reimbursement clarity, positioning itself for continued market share gains and revenue growth in 2026 and beyond [2]. Oncology Franchise - The Oncology franchise generated over $105 million in net revenue for 2025, despite facing complex market dynamics [8].

Not for distribution to United States newswire services or for dissemination in the United StatesVANCOUVER, BC, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Fobi AI Inc. (TSXV:FOBI) (Pink: FOBIF) (the "Company" or "Fobi"), an industry leader in harnessing AI and data intelligence to enable digital transformation, advises that its previously announced non-brokered private placement financing (“Offering”) has been granted an extension to close on or before March 12, 2026, or such other date or dates as may be determined ...

EDGEWOOD, N.Y., Feb. 26, 2026 (GLOBE NEWSWIRE) -- CPI Aerostructures, Inc. (“CPI Aero” or the “Company”) (NYSE American: CVU) announced that Embraer S.A. of Brazil (NYSE: EMBJ) has placed several additional orders totaling $4.2 million against a previously announced Life of Program Agreement to manufacture engine inlet assemblies for the Embraer Phenom 300 business jets. These new orders will see deliveries continue through mid-2026 with continued funding anticipated in support of this life-of-program contr ...

Core Insights - MicroCloud Hologram Inc. has proposed a quantum AI simulator utilizing a hybrid CPU-FPGA method, achieving quantum kernel estimation 500 times faster than traditional CPU simulations [1][4][6] Group 1: Technology Overview - The simulator focuses on application-specific quantum kernels (ASQK) for image classification, implementing core processes on a Field Programmable Gate Array (FPGA) [2][4] - HOLO's design includes an empirical parameterized encoding strategy for image classification, transforming image samples into fixed-dimensional feature vectors for quantum circuit input [3] - The quantum kernel circuit structure employs controlled rotation gates and entanglement gates to enhance global feature correlations, optimizing hardware utilization while maintaining FPGA logic resource utilization below 82% [3][4] Group 2: Performance Validation - Tests on the simulator using datasets like MNIST and Fashion-MNIST show that FPGA-accelerated quantum kernel estimation runs at about 1/500 the time of CPU implementations, achieving classification accuracy comparable to Gaussian kernels [4] - The platform allows for algorithm verification, model comparison, and scalability testing of quantum machine learning algorithms without needing actual quantum hardware [4][6] Group 3: Future Plans - Future developments will expand the simulator's capabilities to support more complex quantum circuit structures and automated circuit-to-hardware mapping compilers [5] - HOLO aims to create multi-node quantum simulation clusters by integrating FPGA acceleration with GPUs or quantum simulation cloud platforms, facilitating hybrid state evolution and noise modeling for hundreds of qubits [5][6] - The company plans to explore quantum-classical collaborative training mechanisms to enable adaptive adjustments of quantum kernel encoding structures during training [5][6] Group 4: Company Background - MicroCloud Hologram Inc. specializes in holographic technology services, including holographic LiDAR solutions and digital twin technology, with cash reserves exceeding 3 billion RMB [8] - The company plans to invest over 400 million USD in various frontier technology fields, including blockchain and quantum computing, aiming to become a global leader in quantum holography and quantum computing technology [8]

In 2025, consolidated turnover (excluding audit) of ŽEMAITIJOS PIENAS, AB group amounts to 340,3 million EUR that, if to be compared with the year 2024, has increased by 10,62 %.Net profit (as without audit) of ŽEMAITIJOS PIENAS, AB group in the year 2025, makes 6 % of the turnover. The person authorized to provide additional information:Arnas Matuzas,Head of the Legal Department +370 444 22308 ...

ROSH-HA`AYIN, Israel, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Kornit Digital Ltd. (“Kornit” or the “Company”) (Nasdaq: KRNT), a global leader in sustainable, on-demand, digital fashion and textile production, announced today that the Company will participate in the 2026 Cantor Global Technology & Industrial Growth Conference and host one-on-one investor meetings. Kornit’s Chief Capital Markets Officer, Andrew G. Backman ("Andy"), will be available for one-on-one investor meetings on Tuesday, March 10, and Wednesd ...